• Donate
  • Contact
Canadian Association of Pompe
  • Home
  • About Us
    • Portraits of Pompe
    • Our Partners
    • Newsletter
  • About Pompe
    • Talk Pompe
    • Webinars
  • Blog
  • Links
  • Connections
Select Page
Amicus Therapeutics Receives Breakthrough Therapy Designation for Pompe Treatment

Amicus Therapeutics Receives Breakthrough Therapy Designation for Pompe Treatment

by Brad Crittenden | Feb 25, 2019 | News

Amicus Therapeutics announced today that they have received Breakthrough Therapy Designation (BTD) for their AT-GAA treatment for Pompe disease.

Recent Posts

  • International Pompe Day 2022
  • Julie
  • Brad
  • Rare Disease Day 2022
  • Maze Therapeutics Starting Phase I Clinical Trial with MZE001, A Substrate Reduction Therapy
  • Terms
  • Privacy

Copyright © 2006 - 2023 Canadian Association of Pompe